Protagenic Therapeutics (PTIX) Competitors $4.76 -0.61 (-11.36%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$4.76 0.00 (-0.11%) As of 05/23/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PTIX vs. CALC, CYCC, DARE, ANVS, EGRX, TENX, GDTC, TPST, CARA, and PULMShould you be buying Protagenic Therapeutics stock or one of its competitors? The main competitors of Protagenic Therapeutics include CalciMedica (CALC), Cyclacel Pharmaceuticals (CYCC), Daré Bioscience (DARE), Annovis Bio (ANVS), Eagle Pharmaceuticals (EGRX), Tenax Therapeutics (TENX), CytoMed Therapeutics (GDTC), Tempest Therapeutics (TPST), Cara Therapeutics (CARA), and Pulmatrix (PULM). These companies are all part of the "pharmaceutical products" industry. Protagenic Therapeutics vs. CalciMedica Cyclacel Pharmaceuticals Daré Bioscience Annovis Bio Eagle Pharmaceuticals Tenax Therapeutics CytoMed Therapeutics Tempest Therapeutics Cara Therapeutics Pulmatrix CalciMedica (NASDAQ:CALC) and Protagenic Therapeutics (NASDAQ:PTIX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, community ranking, profitability, earnings, institutional ownership and risk. Is CALC or PTIX more profitable? CalciMedica's return on equity of -164.24% beat Protagenic Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CalciMedicaN/A -164.24% -103.53% Protagenic Therapeutics N/A -308.97%-228.73% Does the MarketBeat Community prefer CALC or PTIX? CalciMedica received 18 more outperform votes than Protagenic Therapeutics when rated by MarketBeat users. Likewise, 94.74% of users gave CalciMedica an outperform vote while only 0.00% of users gave Protagenic Therapeutics an outperform vote. CompanyUnderperformOutperformCalciMedicaOutperform Votes1894.74% Underperform Votes15.26%Protagenic TherapeuticsOutperform VotesNo VotesUnderperform Votes1100.00% Do insiders & institutionals believe in CALC or PTIX? 8.0% of Protagenic Therapeutics shares are held by institutional investors. 41.5% of CalciMedica shares are held by insiders. Comparatively, 35.0% of Protagenic Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, CALC or PTIX? CalciMedica has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500. Comparatively, Protagenic Therapeutics has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Do analysts rate CALC or PTIX? CalciMedica currently has a consensus target price of $18.00, indicating a potential upside of 900.00%. Given CalciMedica's stronger consensus rating and higher probable upside, research analysts plainly believe CalciMedica is more favorable than Protagenic Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CalciMedica 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Protagenic Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable valuation & earnings, CALC or PTIX? CalciMedica is trading at a lower price-to-earnings ratio than Protagenic Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalciMedicaN/AN/A-$34.36M-$1.56-1.15Protagenic TherapeuticsN/AN/A-$5M-$13.11-0.36 Does the media prefer CALC or PTIX? In the previous week, Protagenic Therapeutics had 13 more articles in the media than CalciMedica. MarketBeat recorded 13 mentions for Protagenic Therapeutics and 0 mentions for CalciMedica. Protagenic Therapeutics' average media sentiment score of 0.18 beat CalciMedica's score of 0.00 indicating that Protagenic Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment CalciMedica Neutral Protagenic Therapeutics Neutral SummaryCalciMedica beats Protagenic Therapeutics on 11 of the 15 factors compared between the two stocks. Get Protagenic Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTIX vs. The Competition Export to ExcelMetricProtagenic TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.80M$6.46B$5.33B$8.31BDividend YieldN/A2.63%5.27%4.10%P/E Ratio-3.758.3626.7119.58Price / SalesN/A258.95395.62135.28Price / CashN/A65.8538.3234.62Price / Book5.736.416.764.50Net Income-$5M$143.73M$3.23B$248.40M7 Day Performance57.10%0.31%0.36%-0.85%1 Month Performance58.29%0.14%7.03%8.09%1 Year Performance-78.21%0.31%18.59%8.75% Protagenic Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTIXProtagenic Therapeutics1.1481 of 5 stars$4.76-11.4%N/A-79.6%$2.80MN/A-3.752Analyst UpgradeCALCCalciMedica2.0041 of 5 stars$1.86-7.0%$18.00+867.7%-66.0%$25.99MN/A-1.7230CYCCCyclacel Pharmaceuticals0.4512 of 5 stars$2.00flatN/A-95.6%$25.92M$43,000.00-0.2114Upcoming EarningsDAREDaré Bioscience1.3865 of 5 stars$2.92+1.0%$12.00+311.0%-46.8%$25.84M$9,784.00-4.9430ANVSAnnovis Bio1.3055 of 5 stars$2.11+17.9%$34.75+1,546.9%-71.9%$25.48MN/A-0.473Gap DownEGRXEagle PharmaceuticalsN/A$1.94flatN/A-46.4%$25.20M$257.55M0.00100Gap UpTENXTenax Therapeutics1.886 of 5 stars$6.02+2.2%$17.50+190.7%+70.4%$24.97MN/A-2.439GDTCCytoMed Therapeutics1.4697 of 5 stars$2.25-3.4%$5.00+122.2%+9.2%$24.62M$69,501.000.00N/AGap UpTPSTTempest Therapeutics1.9517 of 5 stars$6.66-2.8%$30.00+350.5%-85.1%$24.52MN/A-4.3520Gap DownCARACara Therapeutics1.5804 of 5 starsN/A$72.00+∞N/A$24.33M$7.14M-0.2580Gap DownHigh Trading VolumePULMPulmatrix0.5385 of 5 stars$6.50+0.3%N/A+258.4%$23.73M$7.81M-2.4620Analyst Forecast Related Companies and Tools Related Companies CalciMedica Alternatives Cyclacel Pharmaceuticals Alternatives Daré Bioscience Alternatives Annovis Bio Alternatives Eagle Pharmaceuticals Alternatives Tenax Therapeutics Alternatives CytoMed Therapeutics Alternatives Tempest Therapeutics Alternatives Cara Therapeutics Alternatives Pulmatrix Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTIX) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagenic Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagenic Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PTIX Stock Free PTIX Stock Alerts